Trials / Completed
CompletedNCT00529438
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDOMe) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study assesses the tolerability, safety, efficacy and pharmacokinetics of Bardoxolone methyl (RTA 402) in advanced solid tumors and lymphoid malignancies.
Detailed description
Bardoxolone methyl (RTA 402) is a synthetic triterpenoid that has demonstrated significant in vivo single agent anti-cancer activity. This is an open-label phase I dose-escalation study of Bardoxolone methyl (RTA 402) administered orally for the first 21 days of a 28-day cycle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bardoxolone methyl |
Timeline
- Start date
- 2006-04-30
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-09-14
- Last updated
- 2025-05-28
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00529438. Inclusion in this directory is not an endorsement.